Medicinal composition for treating dermatosis, preparation process and use thereof

Abstract

Disclosed is a pharmaceutical composition for treating skin diseases which comprises the following components (by weight ratio): ginseng 20-40 parts, astragalus root 30-80 parts, capsule of weeping forsythia 5-20 parts, ledebouriella root 10-40 parts, notopterygium root 5-30 parts, levisticum 5-50 parts, flavescent sophora root 10-50 parts, phellodendron bark 5-20 parts, broom cypress fruit 10-30parts, cnidium fruit 10-30 parts, centipede, cassia seed 5-20 parts, hornet nest 10-30 parts, licorice root 5-30 parts, herba schizonepetae 5-20 parts, peppermint 5-20 parts, antelope's horn 10-80 parts, cocklebur fruit 10-50 parts, black-tail snake 10-80 parts, dried human placemta 10-30 parts, agkistrodon acutus 10-50 parts, coralbean bark 5-30 parts, secretio bufonis 10-30 parts, ophicalcite 10-50 parts, lead monoxide 10-50 parts, large-leaf gentian root 10-80 parts, and musk 5-20 parts.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating skin diseases, especially pruritus, its preparation method and application. Background technique [0002] Dermatosis is a kind of commonly encountered diseases, and the symptom of dermatosis is divided into two kinds of subjective symptoms and other symptoms. Among them, the subjective symptoms refer to the symptoms that the patient feels subjectively, which are related to the nature and severity of the skin disease and the individual sex of the patient. They mainly include itching, pain, burning sensation and numbness, and the most frequent subjective symptom is itching. The most common subjective symptoms, itching varies in severity, paroxysmal and persistent, localized and extensive. The itching can be mild or severe, continuous or intermittent, it can be whole body or localized; the same pruritus may cause different degrees of itching in different people due to different sensitivit...

AI Technical Summary

Problems solved by technology

But antipruritic medicine in the prior art is medicine for external use substantially, oral medicine is seldom